Research

Partnership Aims to Find New Treatment for Fragile X Syndrome and Autism

Seaside Therapeutics, a licensee of mGluR5 patents invented at Brown and Emory Universities, has recently completed a licensing deal with Roche to advance new treatments for Fragile X Syndrome and autism spectrum disorders.

There are currently no effective pharmacological treatments for these neurodevelopmental disorders. Seaside and Roche hope to change that by creating treatments that address core symptoms and speed up research and development in this field.

In this alliance, Seaside and Roche will focus on developing drugs, include targeting the mGluR5 pathway, to treat fragile X syndrome and autism.

Learn more about this new alliance.